Actinium Pharmaceuticals, Inc. ATNM.OB is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium and bismuth and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company s lead radiopharmaceutical Iomab TM B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase clinical study of Iomab B in refractory and relapsed Acute Myeloid Leukemia AML patients over the age of with a primary endpoint of durable complete remission. The company s second program, Actimab A, is continuing its clinical development in a Phase / trial for newly diagnosed AML patients over the age of in a single arm multicenter trial.
Quote | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
Last: | $6.87 |
---|---|
Change Percent: | -0.3% |
Open: | $6.58 |
Close: | $6.87 |
High: | $6.92 |
Low: | $6.485 |
Volume: | 203,900 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting PR Newswire -- Iomab-B led bone marrow t...
2024-04-15 12:54:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks . Imagine you acquired shares of a popular, richly price...
Message Board Posts | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
Subject | By | Source | When |
---|---|---|---|
Been watching the share price and have to | timberwolf7 | investorshub | 04/11/2023 4:24:43 AM |
whytestocks: $ATNM News Article - Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Po | whytestocks | investorshangout | 02/27/2023 1:05:46 PM |
Results were definitely FDA approvable. Everyone is | Pharmboy46 | investorshub | 02/22/2023 6:38:21 PM |
What's wrong? I don't understand! Down 5$ in | blukky | investorshub | 02/22/2023 6:26:34 PM |
PUMP & DUMP | Lonewolf1 | investorshub | 02/21/2023 9:41:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting PR Newswire -- Iomab-B led bone marrow t...
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting PR Newswire -&...